Trials / Completed
CompletedNCT01703468
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fed conditions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxcarbazepine |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2009-09-01
- Completion
- 2009-10-01
- First posted
- 2012-10-10
- Last updated
- 2018-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01703468. Inclusion in this directory is not an endorsement.